GO:2000525 positive regulation of T cell costimulation: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000525 describes any process that activates or increases the frequency, rate or extent of T cell costimulation, a critical second signal required for full T cell activation.
• IL-2 is a central amplifier of T cell costimulation, promoting survival, proliferation, and effector differentiation of CD8+ and CD4+ T cells [1,6].
• Costimulatory signals integrate with TCR signaling to regulate T cell exhaustion, memory formation, and antitumor immunity [2,5].
• Dysregulation of T cell costimulation contributes to autoimmune diseases, immunodeficiency, and cancer immune evasion [3,7].
• Key genes involved include IL2, IL2RA, IL2RB, CD28, CD80, CD86, ICOS, and PDCD1, among others [1,2,5].
• CRISPR knockout, knock-in, and overexpression models enable functional dissection of costimulatory pathways in primary T cells and cell lines.
Description
T cell costimulation is a fundamental process in adaptive immunity that provides the necessary second signal for full T cell activation, proliferation, and effector function. GO:2000525, positive regulation of T cell costimulation, encompasses any molecular event that enhances the frequency, rate, or extent of this costimulatory signaling. This regulation is essential for mounting effective immune responses against pathogens and tumors while maintaining tolerance to self-antigens [1,6]. The term is particularly relevant to researchers studying T cell biology, immunotherapy, and autoimmune diseases, as manipulating costimulatory pathways can profoundly alter immune outcomes [2,5]. Understanding the positive regulation of T cell costimulation at the molecular level has led to breakthroughs in cancer immunotherapy, including checkpoint blockade and cytokine-based therapies [2,5]. This article synthesizes current knowledge on the mechanisms, key genes, and experimental models used to study this process, providing a resource for researchers aiming to interrogate costimulatory pathways using CRISPR-based approaches.
positive regulation of T cell costimulation At A Glance
| GO ID | GO:2000525 |
|---|---|
| GO term | positive regulation of T cell costimulation |
| Ontology | biological_process |
| Synonym | positive regulation of T cell co-stimulation; positive regulation of T-cell co-stimulation; positive regulation of T-cell costimulation; positive regulation of T lymphocyte costimulation; positive regulation of T-lymphocyte costimulation |
| Major function | Enhances the second signal required for full T cell activation, proliferation, and effector differentiation. |
| Related processes | T cell activation, cytokine signaling, immune checkpoint regulation, T cell exhaustion. |
| Key molecules | IL-2, CD28, ICOS, CD80, CD86, PD-1, and their downstream signaling components. |
| Disease relevance | Autoimmunity, cancer, immunodeficiency, and chronic viral infections. |
What Is GO:2000525?
GO:2000525 is defined as any biological process that activates or increases the frequency, rate, or extent of T cell costimulation. In simpler terms, it refers to the molecular events that boost the secondary signals required for T cells to become fully activated after recognizing an antigen. This includes enhanced interactions between costimulatory receptors and their ligands, increased expression of costimulatory molecules, and downstream signaling that amplifies T cell responses.
Why Is positive regulation of T cell costimulation Important in Cell Biology?
Positive regulation of T cell costimulation is crucial for effective immune responses, as it determines the magnitude and quality of T cell activation. Without adequate costimulation, T cells may become anergic or undergo apoptosis, leading to impaired immunity. Conversely, excessive costimulation can drive autoimmunity and tissue damage. Understanding this process is therefore central to developing therapies for cancer, autoimmune diseases, and infections [1,2,5].
• Enhances T cell activation, proliferation, and survival, which are essential for clearing pathogens and tumors [1,6].
• Regulates the balance between effector and memory T cell differentiation, impacting long-term immunity [6,8].
• Modulates T cell exhaustion in chronic infections and cancer, with IL-2 signaling playing a dual role.
• Influences the efficacy of immune checkpoint inhibitors, such as PD-1 blockade, by altering costimulatory signals.
• Contributes to autoimmune pathology when dysregulated, as seen in diseases like lupus and rheumatoid arthritis [3,7].
• Provides targets for immunotherapy, including engineered IL-2 variants and costimulatory agonists.
• Affects B cell responses and antibody production through T follicular helper cell regulation [3,7].
• Plays a role in antitumor immunity, where costimulatory signals can overcome immunosuppression [4,5].
• Is critical for vaccine-induced immunity and the generation of robust memory responses.
• Offers opportunities for CRISPR-based gene editing to enhance or dampen T cell responses for therapeutic purposes.
What Happens During positive regulation of T cell costimulation?
Initiation of Costimulatory Signals
In simple terms: This is the first step where T cells receive extra 'go' signals from other molecules.
Positive regulation of T cell costimulation begins with the engagement of costimulatory receptors on T cells by their ligands on antigen-presenting cells. Key interactions include CD28 binding to CD80/CD86 and ICOS binding to ICOSL. These interactions lower the threshold for T cell activation and promote IL-2 production [1,6]. The cytokine IL-2 itself acts as a potent costimulatory amplifier, binding to the IL-2 receptor (IL2RA/CD25, IL2RB/CD122, IL2RG/CD132) and triggering JAK-STAT signaling.
Amplification via Cytokine Signaling
In simple terms: Once the initial signals are received, cytokines like IL-2 boost the response further.
IL-2 signaling through STAT5 enhances the expression of effector molecules and promotes survival. Positive regulation involves increased IL-2 secretion by CD4+ T helper cells, which acts in a paracrine manner on CD8+ T cells to augment their expansion and cytotoxic function. Additionally, IL-18 receptor signaling can upregulate the IL2/STAT5/mTOR pathway, further amplifying costimulation in tumor-reactive CD8+ T cells.
Integration with TCR Signaling
In simple terms: The costimulatory signals merge with the primary antigen signal to fully activate T cells.
Costimulatory signals integrate with T cell receptor (TCR) signaling to activate downstream pathways such as PI3K-AKT and MAPK, which drive transcription factors like NF-κB and NFAT. This integration promotes cell cycle entry, cytokine production, and effector differentiation [1,8]. Positive regulation can also involve the aryl hydrocarbon receptor (AhR), which modulates T cell exhaustion in response to IL-2.
Modulation of T Cell Exhaustion and Memory
In simple terms: Costimulation can either push T cells toward exhaustion or memory, depending on the context.
Chronic costimulation, particularly via IL-2, can lead to T cell exhaustion by upregulating inhibitory receptors like PD-1. However, positive regulation of costimulation through PD-1-targeted IL-2 variants can reinvigorate exhausted T cells and enhance antitumor responses. Conversely, transient costimulatory signals favor memory T cell formation, which is critical for long-term immunity [6,8].
Regulation by Transcription Factors
In simple terms: Certain proteins inside the T cell control how strongly costimulation genes are turned on.
Transcription factors such as Aiolos (IKZF3) repress CD4+ T cell cytotoxic programming by reciprocally regulating T follicular helper (TFH) transcription factors and IL-2 sensitivity. This demonstrates that positive regulation of costimulation is balanced by negative regulators to prevent excessive immune activation.
Key Genes Involved in GO:2000525 positive regulation of T cell costimulation
The following genes and proteins are central to the positive regulation of T cell costimulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL2 | Secreted cytokine that promotes T cell proliferation and survival | Key amplifier of costimulation; target for cancer immunotherapy [1,2] |
| IL2RA | Alpha chain of IL-2 receptor (CD25), confers high-affinity binding | Regulates IL-2 sensitivity; marker of activated T cells |
| IL2RB | Beta chain of IL-2 receptor (CD122), shared with IL-15 | Mediates signaling via JAK-STAT; important for CD8+ T cell memory |
| IL2RG | Common gamma chain (CD132), shared by multiple cytokine receptors | Mutations cause X-linked severe combined immunodeficiency |
| CD28 | Costimulatory receptor on T cells binding CD80/CD86 | Provides essential second signal for T cell activation |
| CD80 | Ligand for CD28 and CTLA-4 on antigen-presenting cells | Regulates costimulation strength; target in autoimmunity |
| CD86 | Ligand for CD28 and CTLA-4, expressed on APCs | Similar to CD80; modulates T cell priming |
| ICOS | Inducible costimulator, binds ICOSL | Enhances T follicular helper and effector responses |
| PDCD1 | PD-1, inhibitory receptor that limits costimulation | Target for checkpoint blockade; modulates exhaustion [2,5] |
| STAT5A | Transcription factor downstream of IL-2 receptor | Mediates IL-2-induced gene expression [1,4] |
| STAT5B | Transcription factor downstream of IL-2 receptor | Redundant with STAT5A in IL-2 signaling |
| MTOR | Kinase integrating costimulatory signals | Regulates T cell metabolism and differentiation |
| AKT1 | Serine/threonine kinase in PI3K pathway | Promotes survival and proliferation downstream of costimulation |
| IKZF3 | Aiolos, transcription factor repressing cytotoxic programming | Modulates IL-2 sensitivity and TFH differentiation |
| AHR | Aryl hydrocarbon receptor, senses environmental cues | Regulates T cell exhaustion in response to IL-2 |
| IL18R1 | IL-18 receptor subunit | Enhances IL-2/STAT5/mTOR pathway in CD8+ T cells |
| FOXP3 | Regulatory T cell transcription factor | Modulates costimulation requirements in Tregs |
How Is positive regulation of T cell costimulation Regulated?
Positive regulation of T cell costimulation is tightly controlled by multiple mechanisms. The mTOR pathway integrates nutrient and costimulatory signals to promote T cell differentiation and effector function. IL-2 signaling via STAT5 induces feedback loops that can either enhance or terminate responses. Negative regulators such as PD-1 and CTLA-4 dampen costimulation to prevent autoimmunity [2,5]. Additionally, transcription factors like Aiolos (IKZF3) repress cytotoxic programming and modulate IL-2 sensitivity, illustrating the balance between positive and negative regulation.
positive regulation of T cell costimulation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL2 | Cancer immunotherapy, autoimmunity | IL2 knockout mice; IL2 overexpression in CAR-T cells |
| PDCD1 | Cancer, chronic infection | PDCD1 knockout in primary human T cells; PD-1 overexpression |
| IL18R1 | Pancreatic cancer, T cell exhaustion | IL18R1 knockout in CD8+ T cells; IL18R1 overexpression |
| IKZF3 | Autoimmunity, lymphoma | IKZF3 knockout in CD4+ T cells; point mutations in DNA-binding domain |
| AHR | T cell exhaustion, cancer | AHR knockout mice; AHR overexpression in tumor-infiltrating lymphocytes |
Cancer Immunotherapy
Positive regulation of T cell costimulation is exploited in cancer immunotherapy to boost antitumor T cell responses. Engineered IL-2 variants that selectively bind IL-2Rβγ have shown enhanced antitumor activity with reduced toxicity. PD-1-targeted cis-delivery of IL-2 variants induces multifaceted antitumoral T cell responses in human lung cancer. However, chronic costimulation can lead to exhaustion, as seen in pancreatic cancer models where IL-18 receptor signaling regulates CD8+ T cell exhaustion via the IL2/STAT5/mTOR pathway. Targeting these pathways with CRISPR screens can identify novel therapeutic targets.
Autoimmune Diseases
Dysregulated costimulation contributes to autoimmune diseases such as lupus and rheumatoid arthritis. IL-2-secreting T helper cells promote extra-follicular B cell maturation via a B cell mTOR-AKT-Blimp-1 axis, which can exacerbate autoantibody production. Aiolos (IKZF3) represses CD4+ T cell cytotoxic programming and modulates TFH differentiation, and its dysregulation is linked to autoimmunity. Modulating costimulatory signals is a therapeutic strategy for these conditions.
Chronic Viral Infections
In chronic viral infections, persistent costimulation can drive T cell exhaustion. IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor. Understanding how positive regulation of costimulation affects exhaustion is critical for developing therapies to restore T cell function during chronic infections.
From positive regulation of T cell costimulation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X enhance T cell costimulation? | CRISPR knockout of gene X in primary human T cells followed by activation assays |
| Does a specific point mutation in gene Y alter costimulatory signaling? | CRISPR point mutation knock-in in Jurkat or primary T cells |
| Can overexpression of gene Z boost antitumor immunity? | Lentiviral overexpression of gene Z in CAR-T cells or mouse models |
| What is the role of gene W in T cell exhaustion? | CRISPR knockout of gene W in chronic infection mouse models |
| How does a tagged version of protein V localize during costimulation? | CRISPR knock-in of fluorescent tag (e.g., GFP) at endogenous locus |
| Which genes regulate IL-2 sensitivity? | Genome-wide CRISPR library screening in T cells under IL-2 limiting conditions |
How to Study the positive regulation of T cell costimulation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on costimulation | Identify positive regulators of IL-2 production |
| CRISPR activation (CRISPRa) | Gain-of-function effects on costimulation | Discover genes that enhance T cell activation |
| Flow cytometry | Surface markers and intracellular cytokines | Assess T cell activation and exhaustion |
| ELISA/Luminex | Secreted cytokine levels | Quantify IL-2, IFN-γ, TNF-α |
| Phospho-proteomics | Signaling pathway activation | Map downstream events of costimulation |
| Western blot | Protein expression and phosphorylation | Validate specific signaling nodes |
| Adoptive transfer | In vivo T cell function | Test antitumor efficacy of edited T cells |
| Single-cell RNA-seq | Transcriptional heterogeneity | Identify costimulation-associated gene signatures |
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify positive regulators of T cell costimulation. For example, a screen for genes that enhance IL-2 production upon TCR stimulation can uncover novel costimulatory pathways. These screens are typically performed in Jurkat cells or primary human T cells using lentiviral sgRNA libraries [2,5].
Flow Cytometry and Cytokine Assays
Flow cytometry measures surface expression of costimulatory molecules (e.g., CD25, CD69, PD-1) and intracellular cytokines (e.g., IL-2, IFN-γ, TNF-α). ELISA or Luminex assays quantify secreted cytokines. These methods are used to assess the functional impact of genetic perturbations on costimulation [1,6].
Phospho-Proteomics and Signaling Analysis
Mass spectrometry-based phosphoproteomics can map signaling events downstream of costimulatory receptors. Western blotting for phosphorylated STAT5, AKT, and mTOR provides a targeted view of pathway activation. These techniques help define the molecular mechanisms of positive regulation [4,7].
In Vivo Models
Mouse models of infection, autoimmunity, and cancer are used to study costimulation in a physiological context. Adoptive transfer of CRISPR-edited T cells into tumor-bearing mice allows assessment of antitumor efficacy. These models are essential for translating in vitro findings [2,4,8].
How CRISPR Can Be Used to Study GO:2000525 positive regulation of T cell costimulation
Knockout
CRISPR knockout is used to delete genes involved in positive regulation of T cell costimulation, such as IL2, CD28, or PDCD1, to assess their necessity. For example, PDCD1 knockout in primary human T cells enhances costimulation and antitumor activity. Knockout of negative regulators like Aiolos (IKZF3) can also boost costimulation.
Point Mutation
Point mutations can be introduced to model disease-associated variants or to dissect specific residues required for costimulatory signaling. For instance, mutations in IL2RA that affect IL-2 binding affinity can be engineered to study dose-dependent effects. CRISPR base editing or prime editing enables precise point mutations in primary T cells.
Knock-in
Knock-in of reporter genes (e.g., GFP) or epitope tags at endogenous loci allows tracking of costimulatory molecules. Knock-in of constitutively active mutants, such as a mutant IL2RB, can enhance costimulation. These models are valuable for studying protein localization and dynamics.
Overexpression
Overexpression of costimulatory ligands or cytokines, such as IL-2 or CD80, can amplify T cell responses. Lentiviral overexpression in CAR-T cells is a common strategy to enhance antitumor efficacy. Overexpression models help identify sufficiency of a gene in driving costimulation.
How EDITGENE Supports positive regulation of T cell costimulation Research
Researchers studying positive regulation of T cell costimulation-related genes often need to determine whether a candidate gene is causally involved in enhancing or dampening T cell activation. EDITGENE provides comprehensive CRISPR gene editing services to accelerate this research, from knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of T cell costimulation research.
Frequently Asked Questions About positive regulation of T cell costimulation
What is GO:2000525 positive regulation of T cell costimulation?
GO:2000525 is a Gene Ontology term for any process that activates or increases the frequency, rate, or extent of T cell costimulation, the second signal required for full T cell activation.
What genes are involved in positive regulation of T cell costimulation?
Key genes include IL2, IL2RA, IL2RB, CD28, CD80, CD86, ICOS, PDCD1, STAT5A, STAT5B, MTOR, AKT1, IKZF3, and AHR, among others [1,2,5,7].
How does IL-2 regulate T cell costimulation?
IL-2 binds to its receptor (IL2RA/B/G) and activates JAK-STAT5 signaling, promoting T cell proliferation, survival, and effector function. It acts as a potent costimulatory amplifier [1,6].
What is the role of PD-1 in T cell costimulation?
PD-1 (PDCD1) is an inhibitory receptor that dampens costimulation. Blocking PD-1 with antibodies or genetic knockout enhances T cell responses, which is exploited in cancer immunotherapy [2,5].
Which diseases are associated with dysregulated T cell costimulation?
Dysregulation is linked to cancer, autoimmune diseases (e.g., lupus, rheumatoid arthritis), immunodeficiency, and chronic viral infections [2,3,5,7].
How can CRISPR be used to study positive regulation of T cell costimulation?
CRISPR knockout, knock-in, point mutation, and overexpression models allow functional dissection of costimulatory genes in primary T cells and cell lines, enabling discovery of novel regulators [2,4,7].
What experimental models are used to study T cell costimulation?
Common models include primary human T cells, Jurkat cells, mouse models of infection and cancer, and adoptive transfer of CRISPR-edited T cells [2,4,6,8].
What is the role of mTOR in T cell costimulation?
mTOR integrates costimulatory signals to regulate T cell metabolism, differentiation, and effector function. It is activated downstream of IL-2/STAT5 and PI3K-AKT pathways.
How does Aiolos (IKZF3) regulate T cell costimulation?
Aiolos represses CD4+ T cell cytotoxic programming by reciprocally regulating TFH transcription factors and IL-2 sensitivity, thus modulating costimulatory responses.
What methods are used to measure T cell costimulation?
Flow cytometry, ELISA, phospho-proteomics, CRISPR screens, and in vivo models are commonly used to assess costimulatory signaling and T cell function [1,2,4,6].
Conclusion
Positive regulation of T cell costimulation (GO:2000525) is a cornerstone of adaptive immunity, governing the strength and quality of T cell responses. Its dysregulation underlies cancer, autoimmunity, and chronic infections, making it a prime target for therapeutic intervention. Advances in CRISPR gene editing and high-throughput screening have accelerated the discovery of novel costimulatory regulators, offering new avenues for immunotherapy. Continued research into the molecular mechanisms and key genes involved will inform the development of next-generation treatments.
References
- 1. Spolski R et al.. 2018. Biology and regulation of IL-2: from molecular mechanisms to human therapy.. Nat Rev Immunol 18(10):648-659 PMID: 30089912
- 2. Fusi I et al.. 2025. PD-1-targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer.. Sci Transl Med 17(816):eadr3718 PMID: 40961225
- 3. Faliti CE et al.. 2024. Interleukin-2-secreting T helper cells promote extra-follicular B cell maturation via intrinsic regulation of a B cell mTOR-AKT-Blimp-1 axis.. Immunity 57(12):2772-2789.e8 PMID: 39612915
- 4. Lutz V et al.. 2023. IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model.. Cancer Immunol Res 11(4):421-434 PMID: 36758176
- 5. Liu Y et al.. 2021. IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor.. Nat Immunol 22(3):358-369 PMID: 33432230
- 6. Jobin K et al.. 2025. A distinct priming phase regulates CD8 T cell immunity by orchestrating paracrine IL-2 signals.. Science 388(6743):eadq1405 PMID: 40208984
- 7. Read KA et al.. 2023. Aiolos represses CD4(+) T cell cytotoxic programming via reciprocal regulation of T(FH) transcription factors and IL-2 sensitivity.. Nat Commun 14(1):1652 PMID: 36964178
- 8. Hashimoto M et al.. 2019. Cytokine-Mediated Regulation of CD8 T-Cell Responses During Acute and Chronic Viral Infection.. Cold Spring Harb Perspect Biol 11(1) PMID: 29101105
